Product Images Clopidogrel

This is a description of a medication package. The package contains 30 tablets, with each tablet individually wrapped in unit-dose packaging. The medication is clopidogrel, with each tablet containing 300mg of the active ingredient. The package includes a medication guide that should be dispensed to each patient by the pharmacist. The package should be protected from moisture.*

The text is a table displaying Hazard Ratio for patient baseline characteristics and on-study concomitant medications/interventions for the CURE study. It displays the subgroup, N, Clopidogrel n(%) and Placebo n(%), followed by Favors Clopidogrel and Favors Placebo columns. The table also has some graphs showing the Hazard Ratio(95% CT) for patient sub-categories such as those with heparin/ INWH, Aspirin(mg), GPIIHTIa Antag, Beta-blocker, and Ace Inhibitor. This table is likely part of a medical study analyzing the effectiveness of medications in treating a certain condition.*

The text describes a study (COMMIT) that analyzed the effect of adding Clopidogrel to Aspirin on the Combined Primary Endpoint, stratified by gender, heart rate, and fibrinolytic agent given. The table contains the number of participants in each subgroup and the number and percentage of those who received clopidogrel. The results show the odds ratio in favor of clopidogrel or placebo for each subgroup.*

The figure shows the cumulative event rate for fatal or non-fatal vascular events in the CAPRIE study. The x-axis represents the months of follow-up while the y-axis shows the cumulative event rate percentage. The study compared clopidogrel to another medication and found a statistically significant difference with a P-value of 0.043.*

Each tablet contains 332 mg of clopidogrel bisulfate, equivalent to 10300 mg of clopidogrel base. Store at 25°C (77°F), excursions permitted from 15-30°C (59-86°F). Protect from most. Dispense in a tight container. Usual dosage as directed. Available in 500 tablets with NDC 60505-3532-5. Manufactured for Apotex Corp. by the company Cloridrato de Clopidogrel. Pharmacists must dispense the medication guide provided separately to each patient.*

This is a description of a medication called Clopidogrel. Each film-coated tablet contains 97.875 mg of clopidogrel bisulfate, which is equivalent to 1075 mg of copidogre. The medication should be stored at controlled room temperature between 15°C to 30°C. It should be protected from moisture and dispensed in a tight container. The usual dosage is referred to the package insert. The medication is available in a 30 tablet container, and the pharmacist should dispense the enclosed medication guide to each patient. The medication is manufactured by Apotexnc in Toronto, Ontario. It is manufactured for Westbrook, ME 04092.*

The text describes a figure (Figure 1) showing the effects of co-administering Proton Pump Inhibitors (PPIs) with Clopidogrel 75 mg on exposure to active metabolite AUC. The means and 90% confidence interval of the AUC change relative to Clopidogrel administered alone are displayed for different PPIs including Dextansoprazole 60 mg, Lansoprazole 30mg, Pastoprazole 50mg, and Omeprazole 80 mg.*

The figure shows the cumulative event rate for cardiovascular death, myocardial infarction, and stroke in the CURE study. The percentage of events is plotted against months of follow-up. The placebo group (aspirin only) is compared to the clopidogrel group (plus aspirin). The results indicate a significant reduction in events in the clopidogrel group compared to the placebo group. Other standard therapies were used as appropriate.*

Cumulative event rates for death in the COMMIT study are presented in Figure 4. The text indicates two different percentages of deaths at different times. There is also mention of a proportional reduction and a p-value. The study involved selected patients but it's not clear what patient characteristics were used for selection.*

This figure shows the cumulative event rates for the combined endpoint of re-infarction, stroke, or death in the COMMIT study. The placebo group had 2310 patients with events, representing 10.1% of the group. The clopidogrel group had 2121 patients with events, representing 8.2% of the group. This corresponds to a 9% proportional risk reduction, with a 6 with death, and a 7 re-intarction or stroke before the first discharge. The x-axis represents days since randomization, up to 28 days, and all treated patients received aspirin.*

Clopidogrel is a USP tablet with 75mg of clopidogrel bisufae equivalent to 75 mg of clopidogrel base. The tablets should be stored at 25°C (77°F) with excursions permitted to 15-30°C (59° to 86°F) and protected from moisture. The manufacturer is Onetex Corp in Charleston, FL with the tablets made in Canada. There is a lot number and expiration date provided. Dosage details are mentioned in the package insert.*